An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

SARS-CoV-2 variants that attenuate antibody neutralization could jeopardize vaccine efficacy. We recently reported the protective activity of an intranasally administered spike protein-based chimpanzee adenovirus-vectored vaccine (ChAd-SARS-CoV-2-S) in animals, which has advanced to human trials. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Ahmed O., Shrihari, Swathi, Gorman, Matthew J., Ying, Baoling, Yaun, Dansu, Raju, Saravanan, Chen, Rita E., Dmitriev, Igor P., Kashentseva, Elena, Adams, Lucas J., Mann, Colin, Davis-Gardner, Meredith E., Suthar, Mehul S., Shi, Pei-Yong, Saphire, Erica Ollmann, Fremont, Daved H., Curiel, David T., Alter, Galit, Diamond, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270739/
https://www.ncbi.nlm.nih.gov/pubmed/34289385
http://dx.doi.org/10.1016/j.celrep.2021.109452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270739/
https://www.ncbi.nlm.nih.gov/pubmed/34289385
http://dx.doi.org/10.1016/j.celrep.2021.109452

Ejemplares similares